Saturday, 17 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

ASETEK Stock Bearish By 34% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ASETEK (Oslo Børs Benchmark Index_GI: ASTK.OL) dropped by a staggering 34.7% in 21 sessions from kr5.59 to kr3.65 at 20:24 EST on Monday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is rising 1.09% to kr1,226.44, after three consecutive sessions in a row of gains.

About ASETEK

Asetek A/S, together with its subsidiaries, engages in the designing, developing, and marketing of liquid cooling solutions in Asia, Europe, and the Americas. The company operates through Liquid cooling, Data center and SimSports segments. Its products are used in personal computers, servers, and data centers to provide improved performance, acoustics, and energy efficiency. It serves original equipment manufacturers, resellers, and channel partners. The company was founded in 1997 and is headquartered in Aalborg, Denmark.

Earnings Per Share

As for profitability, ASETEK has a trailing twelve months EPS of kr-0.55.

Volume

Today's last reported volume for ASETEK is 221202 which is 44.63% above its average volume of 152935.

More news about ASETEK (ASTK.OL).

Categories

stockMarket

Tags

Stock PriceASETEKPrice DownMarket Session NowStock Price DownStock Market NowMarket SessionASTK.OLStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com